AEON Biopharma Balance Sheet Health
Financial Health criteria checks 0/6
AEON Biopharma has a total shareholder equity of $-27.9M and total debt of $13.3M, which brings its debt-to-equity ratio to -47.6%. Its total assets and total liabilities are $5.7M and $33.7M respectively.
Key information
-47.6%
Debt to equity ratio
US$13.29m
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.44m |
| Equity | -US$27.95m |
| Total liabilities | US$33.68m |
| Total assets | US$5.73m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AEON has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AEON has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AEON has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AEON's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: AEON's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if AEON's interest payments on its debt are well covered by EBIT.